Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment

A Sundlöv; K Sjögreen-Gleisner

doi:10.1016/j.clon.2020.10.020

Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment

Clin Oncol (R Coll Radiol). 2021 Feb;33(2):92-97. doi: 10.1016/j.clon.2020.10.020. Epub 2020 Nov 12.

Authors

A Sundlöv¹, K Sjögreen-Gleisner²

Affiliations

¹ Department of Oncology, Skåne University Hospital, Lund, Sweden; Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden. Electronic address: anna.sundlov@med.lu.se.
² Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden.

PMID: 33189510
DOI: 10.1016/j.clon.2020.10.020

Abstract

Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed activity of the radiopharmaceutical (¹⁷⁷Lu-DOTATATE) and a fixed number of treatment cycles. Several research groups around the world have studied different approaches of further improving on the results of peptide receptor radionuclide therapy, with many promising retrospective and prospective clinical studies having been published over the years. In this overview, we summarise some of the most promising strategies identified so far.

Trial registration: ClinicalTrials.gov NCT03511664 NCT03872778.

Keywords: (177)Lu-DOTATATE; PRRT; individualised; neuroendocrine tumours; personalised; radionuclide therapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Neuroendocrine Tumors* / radiotherapy
Precision Medicine*
Prospective Studies
Radioisotopes
Receptors, Peptide
Retrospective Studies

Substances

Radioisotopes
Receptors, Peptide

Associated data

ClinicalTrials.gov/NCT03511664
ClinicalTrials.gov/NCT03872778